Angiogenesis in primary central nervous system lymphoma (PCNSL)

Overview of attention for article published in Journal of Neuro-Oncology, April 2007

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

patent: 11 patents

Citations

dimensions_citation: 46 Dimensions

Readers on

mendeley: 27 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 11 patents that reference this research output.

Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability

Grant US-11534488-B2

United States of America

Anti-CD100 antibodies and methods for using the same

Grant US-11274149-B2

United States of America

Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit…

Grant US-11078295-B2

United States of America

Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to…

Grant US-10526414-B2

United States of America

Use of semaphorin-4D binding molecules to promote neurogenesis following stroke

Grant US-10494440-B2

United States of America

USE OF SEMAPHORIN-4D BINDING MOLECULES FOR MODULATION OF BLOOD BRAIN BARRIER PERMEABILITY

Grant EP-2766093-B1

European Patent Office

Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D…

Grant US-9828435-B2

United States of America

Anti-CD100 neutralizing antibodies and methods of using the same

Grant US-9676840-B2

United States of America

Anti-CD100 antibodies and methods of using the same

Grant US-9605055-B2

United States of America

Use of semaphorin-4D binding molecules for treatment of atherosclerosis

Grant US-9512224-B2

United States of America

Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases

Grant US-9243068-B2

United States of America